Literature DB >> 17216202

The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics.

Michalis V Karamouzis1, Panagiotis A Konstantinopoulos, Athanasios G Papavassiliou.   

Abstract

The signal transducer and activator of transcription (STAT) proteins are a family of latent cytoplasmic transcription factors, which form dimers when activated by cytokine receptors, tyrosine kinase growth factor receptors as well as non-receptor tyrosine kinases. Dimeric STATs translocate to the nucleus, where they bind to specific DNA-response elements in the promoters of target genes, thereby inducing unique gene expression programs often in association with other transcription regulatory proteins. The functional consequence of different STAT proteins activation varies, as their target genes play diverse roles in normal cellular/tissue functions, including growth, apoptosis, differentiation and angiogenesis. Certain activated STATs have been implicated in human carcinogenesis, albeit only few studies have focused into their role in lung tumours. Converging evidence unravels their molecular interplays and complex multipartite regulation, rendering some of them appealing targets for lung cancer treatment with new developing strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216202     DOI: 10.1007/s00109-006-0152-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   5.606


  72 in total

Review 1.  Inhibitors of cytokine signal transduction.

Authors:  Samuel Wormald; Douglas J Hilton
Journal:  J Biol Chem       Date:  2003-11-07       Impact factor: 5.157

2.  Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Authors:  Faye M Johnson; Lee M Krug; Hai T Tran; Stephanie Shoaf; Victor G Prieto; Pheroze Tamboli; Beverly Peeples; Jyoti Patel; Bonnie S Glisson
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

3.  Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.

Authors:  Yasuharu Niwa; Hiroaki Kanda; Yuko Shikauchi; Akio Saiura; Kenichi Matsubara; Tomoyuki Kitagawa; Junji Yamamoto; Takahiko Kubo; Hirohide Yoshikawa
Journal:  Oncogene       Date:  2005-09-22       Impact factor: 9.867

4.  Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

Authors:  Purva Bali; Michael Pranpat; Ramona Swaby; Warren Fiskus; Hirohito Yamaguchi; Maria Balasis; Kathy Rocha; Hong-Gang Wang; Victoria Richon; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

Review 5.  Transcription factors and neoplasia: vistas in novel drug design.

Authors:  Mihalis V Karamouzis; Vassilis G Gorgoulis; Athanasios G Papavassiliou
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

6.  Stat1 and SUMO modification.

Authors:  Li Song; Samita Bhattacharya; Ali A Yunus; Christopher D Lima; Christian Schindler
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

7.  The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.

Authors:  Karen Liby; Nga Voong; Charlotte R Williams; Renee Risingsong; Darlene B Royce; Tadashi Honda; Gordon W Gribble; Michael B Sporn; John J Letterio
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

8.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

9.  Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck.

Authors:  Istvan Arany; San-H Chen; Judit K Megyesi; Karen Adler-Storthz; Z Chen; Srinivasan Rajaraman; Istvan A Ember; Stephen K Tyring; Miriam M Brysk
Journal:  Cancer Lett       Date:  2003-09-10       Impact factor: 8.679

10.  The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells.

Authors:  Kerstin Nagel-Wolfrum; Claudia Buerger; Ilka Wittig; Karin Butz; Felix Hoppe-Seyler; Bernd Groner
Journal:  Mol Cancer Res       Date:  2004-03       Impact factor: 5.852

View more
  8 in total

1.  Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.

Authors:  Jennifer M Speth; Loka R Penke; Joseph D Bazzill; Kyung Soo Park; Rafael Gil de Rubio; Daniel J Schneider; Hideyasu Ouchi; James J Moon; Venkateshwar G Keshamouni; Rachel L Zemans; Vibha N Lama; Douglas A Arenberg; Marc Peters-Golden
Journal:  JCI Insight       Date:  2019-10-17

Review 2.  IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review.

Authors:  Vasiliki Galani; Michalis Kastamoulas; Anna Varouktsi; Evangeli Lampri; Antigoni Mitselou; Dimitrios L Arvanitis
Journal:  Clin Exp Med       Date:  2016-07-14       Impact factor: 3.984

3.  Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells.

Authors:  Manesh Chittezhath; Gagan Deep; Rana P Singh; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

4.  Preconditioning mediated by sublethal oxygen-glucose deprivation-induced cyclooxygenase-2 expression via the signal transducers and activators of transcription 3 phosphorylation.

Authors:  Eun J Kim; Ami P Raval; Miguel A Perez-Pinzon
Journal:  J Cereb Blood Flow Metab       Date:  2008-04-09       Impact factor: 6.200

Review 5.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

6.  The Antitumor Effect of C-terminus of Hsp70-Interacting Protein via Degradation of c-Met in Small Cell Lung Cancer.

Authors:  Sung Ho Cho; Jong In Kim; Hyun Su Kim; Sung Dal Park; Kang Won Jang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-06-05

7.  SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells.

Authors:  Sylvia Müller; Yuan Chen; Torsten Ginter; Claudia Schäfer; Marc Buchwald; Lienhard M Schmitz; Jana Klitzsch; Alexander Schütz; Andrea Haitel; Katharina Schmid; Richard Moriggl; Lukas Kenner; Karlheinz Friedrich; Claude Haan; Iver Petersen; Thorsten Heinzel; Oliver H Krämer
Journal:  Oncotarget       Date:  2014-05-30

8.  The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma.

Authors:  Dorota Pastuszak-Lewandoska; Daria Domańska-Senderowska; Adam Antczak; Jacek Kordiak; Paweł Górski; Karolina H Czarnecka; Monika Migdalska-Sęk; Ewa Nawrot; Justyna M Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.